USAMRIID signs biodefense vaccines contract

The U.S. Army Medical Research Institute of Infectious Diseases has signed a contract with Purdue Research Park’s West Lafayette, Indiana-based Bioscience Vaccines, Inc., to test the company’s Matrix Immune Modulator technology with biodefense vaccines.

Matrix Immune Modulator is a naturally-occurring biomaterial, developed by the life science company, which can be added to vaccines to make them more effective while reducing the vaccine’s cost. The contract will allow Bioscience Vaccines, Inc., to test MIM on biodefense vaccines for soldiers.

U.S. soldiers go through a series of eight injections with biodefense vaccines as part of their physical training and preparation. Using the MIM technology on the current vaccines may enable soldiers to go through fewer injections. This may also be possible with vaccines for the U.S. civilian population which can strengthen national security.

"We are pleased with the opportunity to collaborate with the U.S. Department of Defense in the development of their biodefense strategies," Anthony Hubbard, the executive vice president of Bioscience Vaccines, said. "Pending the results of the agreement, BVI's next step will be to leverage the results to obtain additional funding for follow-on testing and to move onto the second phase of testing with the U.S. Army Medical Research Institute of Infectious Diseases to further develop a vaccine to protect soldiers and the public from potential biowarfare."

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.